Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market Size in the 7MM is anticipated to increase at a significant CAGR by 2036, estimates DelveInsight

DelveInsight's "Gastroenteropancreatic Neuroendocrine Tumors Market Insight, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Gastroenteropancreatic Neuroendocrine Tumors Market @ Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Gastroenteropancreatic Neuroendocrine Tumors Market Report

• The US contributed to the highest incident cases of NETs. The total incident cases of NETs in the United States in 2025 were 31,000.
• According to the secondary search, net project, the incidence of malignant GEP-NET during 2000-2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.
• As per the secondary sesrch, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 ± 15 years, and the sex distribution was nearly equal, with 51% men and 49% women in Spain.
• Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).
• The most common primary tumor site was the pancreas (52%), followed by the jejunum-ileum (23%). At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.
• The leading Gastroenteropancreatic Neuroendocrine Tumors Companies such as Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
• Promising Gastroenteropancreatic Neuroendocrine Tumors Therapies such as LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others.

Stay ahead in the competitive landscape of the Gastroenteropancreatic Neuroendocrine Tumors Market @ Gastroenteropancreatic Neuroendocrine Tumors Treatment Market Size- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Segmentation in the 7MM

• Total Incident Cases of NET
• Total Incident Cases of GEP-NET
• Grade-specific Incident Cases of GEP-NET
• Functional status Incident Cases of GEP-NET
• Stage-specific Incident Cases of GEP-NET
• SSR Positive Incident Cases of GEP-NET
• Total Treated Cases of GEP-NET

Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumors epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumors Prevalence- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroenteropancreatic Neuroendocrine Tumors Treatment Landscape

Gastroenteropancreatic Neuroendocrine Tumors treatments usually induce tumor stabilization for a limited length of time. Enormous effort is being put into developing novel approaches to overcome treatment-related resistance in patients with advanced and progressive GEP-NETs. The relatively small number of patients included in clinical studies, as well as the relatively slow course of the disease, make it difficult to evaluate the response rates for new therapies and their influence on survival.

Approved Therapies for Gastroenteropancreatic Neuroendocrine Tumors

• LUTATHERA (lutetium Lu 177 DOTATATE): Novartis

LUTATHERA, is indicated for adult patients with somatostatin receptor-positive GEP-NET. Peptide receptor radionuclide therapy (PRRT), either with 90-Yttrium-labeled compounds or with LUTATHERA (lutetium-177 oxodotreotide) is approved for supply in Australia and is listed on the Australian Register of Therapeutic Goods (ARTG) under ARTG number 455452, with a registration date of November 2025. In September 2017, the EMA approved LUTATHERA for the treatment of GEP-NET. This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NET.

• SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals

SOMATULINE DEPOT is a SSA indicated for the treatment of adult patients with unresectable well or moderately differentiated, locally advanced, or metastatic GEP-NET to improve progression-free survival. The drug is also approved for the treatment of adults with carcinoid syndrome by reducing the frequency of short-acting SSA rescue therapy. The drug is administered subcutaneously.

Gastroenteropancreatic Neuroendocrine Tumors Pipeline Analysis

• ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich

ITM-11 (n.c.a. 177Lu-edotreotide), being developed by ITM Isotope Technologies Munich, is an innovative targeted radionuclide therapy agent consisting of two components: firstly, Edotreotide (DOTATOC). It is currently being investigated in two Phase III clinical trials, COMPETE (GEP-NET G1/G2) and COMPOSE (GEP-NET G3/G4). While COMPETE is evaluating ITM-11 for the treatment of patients with Grade 1 and Grade 2 GEP-NET, the radiopharmaceutical candidate is also being investigated in COMPOSE, for patients with well-differentiated high Grade 2 and Grade 3 GEP-NET. ITM Isotope Technologies Munich announced that the FDA completed its filing review and accepted the company's New Drug Application for 177Lu-edotreotide.

• CAM2029: Camurus AB

CAM2029, being developed by Camurus AB, is a ready-to-use, long-acting, subcutaneous depot of octreotide under development to treat rare diseases, acromegaly, GEP-NET, and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. The drug is currently being evaluated in a Phase III SORENTO study (Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine Tumors) in patients with GEP-NET. According to the company's presentation, they anticipated to present PFS readout data of Phase III (SORENTO) clinical trial in mid to late 2026

Discover the future of Gastroenteropancreatic Neuroendocrine Tumors Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Gastroenteropancreatic Neuroendocrine Tumors Market Drivers and Barriers- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastroenteropancreatic Neuroendocrine Tumors Market Outlook

The GEP-NET market is undergoing a steady shift as deeper insights into tumor biology and receptor expression patterns reshape treatment approaches. Historically characterized by slow-growing but complex disease behavior, GEP-NET management is now benefiting from advances in targeted pathways, including mTOR inhibition and somatostatin receptor directed strategies. These developments are improving disease stabilization and delaying progression, particularly in patients with well-differentiated tumors.

Gastroenteropancreatic Neuroendocrine Tumors Drug Uptake

The uptake of therapies in GEP-NET is expected to vary based on clinical positioning, mechanism of action, and stage of development. Approved targeted therapy such as LUTATHERA (lutetium Lu 177 DOTATATE) is projected to demonstrate steady uptake, driven established efficacy and physician familiarity in advanced disease settings. In contrast, pipeline candidates' surufatinib is expected to follow a moderate uptake trajectory, reflecting its investigational status and gradual adoption as clinical evidence emerges.

Gastroenteropancreatic Neuroendocrine Tumors Drugs and Companies

• ITM-11: ITM Isotope Technologies Munich
• CAM2029: Camurus
• RYZ101: RayzeBio
• Lanreotide: Merck Sharp & Dohme
• arginine/lysine: Advanced Accelerator
• Temozolomide (TMZ): Ipsen
• Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
• RYZ101: RayzeBio, Inc.
• CAM2029: Camurus AB
• Everolimus: Novartis
• PEN-221: Tarveda Therapeutics
• Lutathera: Progenics Pharmaceuticals
• Ibrutinib: Pharmacyclics

From Gastroenteropancreatic Neuroendocrine Tumors Market Size to emerging drugs-find it all in our latest report. Read now @ https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Gastroenteropancreatic Neuroendocrine Tumors Companies- Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
• Gastroenteropancreatic Neuroendocrine Tumors Therapies- LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others.
• Gastroenteropancreatic Neuroendocrine Tumors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL's views, Analyst's views, Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement

Explore the dynamics of the Gastroenteropancreatic Neuroendocrine Tumors Market with DelveInsight. @ Gastroenteropancreatic Neuroendocrine Tumors Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Key Insights
2. Gastroenteropancreatic Neuroendocrine Tumors Market Report Introduction
3. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance
4. Executive Summary of Gastroenteropancreatic Neuroendocrine Tumors
5. Gastroenteropancreatic Neuroendocrine Tumors Market Disease Background and Overview
6. Methodology
7. Gastroenteropancreatic Neuroendocrine Tumors Epidemiology and Patient Population
8. Patient Journey
9. Gastroenteropancreatic Neuroendocrine Tumors Marketed Drugs
10. Gastroenteropancreatic Neuroendocrine Tumors Emerging Drugs
11. Gastroenteropancreatic Neuroendocrine Tumors: Seven Major Market Analysis
12. KOL Views
13. SWOT Analysis
14. Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs
15. Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.